Dthera Sciences Chief Technology Officer to Speak at CES Digital Health Summit
SAN DIEGO, CA / ACCESSWIRE / January 7, 2019 /Dthera™ Sciences (OTCQB: DTHR ), the leading digital therapeutic company focusing on the elderly, is pleased to announce that Dave Keene, Co-Founder and Chief Technology Officer will be speaking at CES, Digital Health Summit, A Brain and Mental Health Crisis Intervention. CES 2019, is January 8-11, 2019 in Las Vegas.
Mr. Keene will be discussing the future of digital therapeutics and specifically treatments for those suffering from Alzheimer’s and other dementias. Dthera’s development-stage digital therapeutic device, DTHR-ALZ, has been granted Breakthrough Device designation by the FDA for the treatment of the symptoms of Alzheimer’s disease.
Before co-founding Dthera Sciences, Mr. Keene was the Sr. Software Architect for the Playstation Network, Sony’s worldwide content delivery platform for video games, movies and music. He is a 20 year veteran of the technology industry who has specialized in content delivery of large scale digital infrastructure.
The discussion will include a panel of leaders in digital innovation, medicine and senior care. The session will be held from 1:00 - 2:55 PM on Wednesday, January 9 at the Venetian Resort, Level 4 Lando 4305, in Las Vegas, NV.
About Dthera Sciences
Dthera Sciences (OTCQB: DTHR) is the leading digital therapeutic company focusing on the elderly. The San Diego based, publicly traded company is working to improve the lives of seniors and individuals suffering from neurodegenerative diseases, as well as those who care for them. Dthera is developing DTHR-ALZ, a medical device that has been granted Breakthrough Device designation by the FDA for the mitigation of the symptoms of agitation and depression associated with Alzheimer’s disease. To the company’s knowledge, DTHR-ALZ is the first product to receive Breakthrough Device designation for the treatment of Alzheimer’s disease, and Dthera Sciences is only the second digital therapeutic company to receive this designation. If granted approval by the FDA, DTHR-ALZ would become the first non-pharmacological prescription treatment for the symptoms of Alzheimer’s disease. Please see www.dthera.com for more information.
Forward Looking Statement
This press release contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995, regarding the research, development and commercialization of therapeutic products and technologies, as well as the Company’s efforts to increase its customer base. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of the statements made, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. These forward-looking statements are made as of the date of this press release, and the Company expressly disclaims any intention or obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Readers are urged to read the risk factors set forth in the Company’s most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q, and other filings made with the SEC. Copies of these reports are available from the SEC’s website at www.sec.gov or without charge from the Company.
Geno Kostikov, Corporate Development
Marek Ciszewski, J.D., Managing Director, Head of Life Sciences
Liolios Group, Inc.
SOURCE: Dthera Sciences